Respiratory Diseases

 
US Adults Lagging in Flu, COVID-19, and RSV Vaccination: Daily Dose
December 18, 2024

Your daily dose of the clinical news you may have missed.

Expert Perspectives 2024: Biologics for Management of COPD with MeiLan K Han, MD, MS
December 12, 2024

The GOLD report committee member highlights advances in knowledge of COPD phenotypes and the new role for biologic medications in this year's video series.

The Biggest Challenge with COVID-19 Right Now: An Interview with NFID Medical Director Robert Hopkins, Jr, MD
December 12, 2024

Hopkins, of the National Foundation for Infectious Diseases, is frustrated by the diminished societal response to the virus' circulation including ongoing low vaccination rates.

New COVID-19 Vaccination Guidance for Older Adults & High-Risk Groups: A Conversation with NFID Medical Director Robert Hopkins, Jr, MD
December 09, 2024

Guidance from the Advisory Committee on Immunization Practices on best practices for COVID-19 vaccination continues to evolve, Hopkins explained.

Macrobid Allergy? Seen in the ED
December 04, 2024

A woman in her mid-50s arrives at the ED for suspected anaphylaxis; SOB has not responded to epinephrine and steroids. Does the CT scan suggest a Dx?

"Be Vigilant About Risk Factors for COPD, Aggressive with Questions About Symptoms," Expert Advises Primary Care
November 25, 2024

COPD expert MeiLan K Han, MD, MS, says that in the absence of a definitive single tool to assess for COPD, probing patients for risk factors and symptoms is essential.

2025 GOLD Report on COPD Addresses Cardiovascular Risk in New Section: MeiLan Han, MD, MS, Highlights Rationale
November 22, 2024

Cardiovascular comorbidities in adults with COPD are linked to poor outcomes including reduced QoL, increased hospitalizations, and greater risk of mortality, Han explains.

Respiratory Virus Season 2024-2025: Expert Insights to Help Primary Care Prepare
November 11, 2024

Insights on how to manage the "triple threat" of flu, RSV, and COVID-19 this season.

Social, Racial Disparities in Flu, COVID-19, RSV Vaccine Uptake: Daily Dose
October 31, 2024

Your daily dose of the clinical news you may have missed.

Investigational RSV Vaccine Yields Positive Preliminary Data in Head-to-Head Comparison with Arexvy
October 29, 2024

Preliminary phase 1 data showed that RSV neutralizing antibodies for non-adjuvanted SCB-1019 matched GSK’s AS01E-adjuvanted RSV vaccine, Arexvy.